Purpose: To compare and analyse chemoradiotherapy with either weekly docetaxel or weekly cisplatin for treatment of locally advanced head and neck cancer in terms of tumor response and toxicities. Methods: This was a comparative analytical study. Adult patients (age ≥ 18 years) with LAHNSCC planned for chemoradiation and Karnofsky performance status of >70% were randomly assigned in 1:1 to either radiation with concurrent docetaxel 20mg/ once weekly or concurrent cisplatin 30mg/ m2 for a maximum of six cycles. Comparison of treatment response and acute and late toxicities were done. Results: A total of 50 patients were enrolled in the study between September 2022 and February 2024. The overall response rate was slightly higher in the DocetaxelRT arm compared to the Cisplatin-RT arm (87% vs. 80%). Complete response rates were 34.8% in the Docetaxel-RT group and 20% in the Cisplatin-RT group (P = 0.25), while partial response rates were 52.8% and 60%, respectively (P = 0.58)  In terms of toxicity, Grade III mucositis was significantly more common in the Docetaxel-RT arm (65.2%) compared to the Cisplatin-RT arm (28%). Additionally, the incidence of grade 3 acute skin reactions was higher with Docetaxel-RT (28.1% vs. 4%), as was the occurrence of subcutaneous fibrosis at six months posttreatment (13% vs. 8%).  Conclusion: Weekly Docetaxel (20 mg/m²) administered concurrently with radiotherapy in patients with locally advanced head and neck cancer demonstrates a favorable toxicity profile and comparable efficacy to weekly Cisplatin. Further validation through larger phase II/III trials and multicentre studies is warranted to optimize dosing strategies and assess long-term outcomes, including survival benefits.